← Back to the boardHill
FDA's draft guidance on potency assessment for active immunotherapy products is open for public comment under docket FDA-2026-D-8561 until November 19, 2026.
Why it’s here: An FDA draft guidance on potency assessment for active immunotherapy products is a federal regulatory action in the biotechnology area (FDA regulation of novel therapies), with an open public comment period, making it relevant to DC policy readers.
Item
11:59 PMAgencyFDAFDA's draft guidance on potency assessment for active immunotherapy products is open for public comment under docket FDA-2026-D-8561 until November 19, 2026.Comment deadlineBiotechDetails
About
- Food and Drug Administration